Antagonist Protocol in Poor Responders

• Register: ClinicalTrials.gov
• Last refreshed on: 15 November 2021
• Main ID: NCT02195947
• Date of registration: 18/07/2014
• Prospective Registration: No
• Primary sponsor: Cairo University
• Public title: Antagonist Protocol in Poor Responders
• Scientific title: Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial
• Date of first enrolment: July 2014
• Target sample size: 141
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02195947
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 4

Countries of recruitment

Egypt

Contacts

• Name: Yomna A Bayoumi, MD
• Affiliation: Cairo University

Key inclusion & exclusion criteria

Inclusion Criteria:

- females fulfilling the criteria of the ESHRE consensus 2011:

- at least two of the following three features must be present:

- dvanced maternal age (=40 years) or any other risk factor for POR

- previous POR (=3 oocytes with a conventional stimulation protocol)

- an abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).

Exclusion Criteria:

- women who suffer from any other cause of infertility other than poor ovarian reserve

- refusal of the patient to consent for using her data in the study.



Age minimum: 20 Years
Age maximum: 45 Years
Gender: Female

Health Condition(s) or Problem(s) studied

Female Infertility Due to Diminished Ovarian Reserve

Intervention(s)

Drug: Growth Hormone

Primary Outcome(s)

Live birth rate [Time Frame: Up to 9 months]

Secondary Outcome(s)

Clinical pregnancy rate [Time Frame: Up to 5 weeks]

Secondary ID(s)

72014

Source(s) of Monetary Support

Please refer to primary and secondary sponsors